TLX - CIK 0002007191
Telix Pharmaceuticals Ltd trades as TLX and has a market capitalization of $3.20 B, making it the #1751 largest US-listed company by market value. This page tracks Telix Pharmaceuticals Ltd through 95 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| 6-K | - | 2026-05-21 |
| New insider ownership | 3 | 2026-05-18 |
| New insider ownership | 3 | 2026-05-18 |
| New insider ownership | 3 | 2026-05-18 |
| Insider trade | 4 | 2026-05-06 |
| 6-K | - | 2026-04-23 |
| 6-K | - | 2026-04-21 |
| 6-K | - | 2026-04-20 |
Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
The largest companies sharing Telix Pharmaceuticals Ltd's SEC industry classification (pharmaceutical preparations).
Telix Pharmaceuticals Ltd (TLX) has a market capitalization of $3.20 B as of 2026-06-10, ranking #1751 among US-listed companies.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.